Abstract:Objectives Multiple warfarin pharmacogenetic algorithms have been published and been confirmed to predict warfarin dose more accurately than clinical algorithm or fixed-dose approach. However, their performance in Chinese patients has never been evaluated. We sought to compare the performance of published warfarin pharmacogenetic algorithms in a cohort of Chinese patients under warfarin anticoagulation. Methods The study population consisted of 282 unrelated Han-Chinese patients consecutively admitted to the General Hospital of Chinese People9s Liberation Army between January 2008 and July 2011. The patients had all undergone warfarin anticoagulation for various indications and were stably controlled with a target international normalisation ratio (INR) of 1.6–2.5. Genomic DNA extraction from each patient was followed by genotyping to detect the polymorphisms of CYP2C9*3 (rs1057910), VKORC1 −1639 G/A (rs9923231), and CYP4F2*3 (rs2108622) respectively, using standard techniques. A total of 8 eligible pharmacogenetic algorithms were selected for performance comparison. The performance of each algorithm was evaluated by calculating the percentage of patients whose predicted dose fell within 20% of their actual therapeutic dose (percentage within 20%), and the mean absolute error (MAE) between each predicted dose and actual stable dose. Results In the entire cohort, the pharmacogenetic algorithms could predict warfarin dose with the average MAE of 0.87±0.17 mg/day (0.73–1.17 mg/day), and the average percentage within 20% of 43.8%±8.1% (29.1–52.1%). By pair wise comparison, warfarin dose prediction was significantly more accurate with the algorithms derived from Asian patients (48.6–50.0%) than those from Caucasian patients (29.1–39.7%; OR 1.61–3.36, p≤0.02). Algorithms with additional covariates of INR values or CYP4F2*3 performed better than those without the covariates (adding INR: OR: 1.71 (1.08–2.72), p=0.029; adding CYP4F2*3: OR: 2.67 (1.41–5.05), p=0.004). When the patients were stratified according to the dose range, the algorithms from Caucasian and racially mixed populations tended to perform better in higher dose group (≥4.5 mg/day), and algorithms from Asian populations performed better in intermediate dose group (1.5–4.5 mg/day). None of the algorithms performed well in lower dose group (≤1.5 mg/day). Conclusions Our study indicated that none of the eligible pharmacogenetic algorithms could perform the best for all dosing ranges in the present cohort of Chinese patients under warfarin anticoagulation. It may be important to consider the ethnic and clinical specific characteristics when choosing the appropriate algorithm for a local service population. A more refinement pharmacogenetic algorithm combining 3 genotypes (CYP2C9, VKORC1 and CYP4F2) and clinical factors with INR response could potentially improve the warfarin dose prediction in Chinese patients.

The Accuracy of Warfarin Dosage Based on VKORC1 and CYP2C9 Phenotypes in a Chinese Population

Comparative Performance of Gene-Based Warfarin Dosing Algorithms in Chinese Patients

Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients.

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

Effects of CYP2C9 and VKORC1 Genetic Polymorphisms in Chinese Han Population on Maintenance Dosage of Warfarin

DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation

Estimation of the Warfarin Dose with A Pharmacogenetic Refinement Algorithm in Chinese Patients Mainly under Low-Intensity Warfarin Anticoagulation

VKORC1 Diplotype-Derived Dosing Model to Explain Variability in Warfarin Dose Requirements in Asian Patients

Accuracy Assessment of Pharmacogenetic Algorithms for Warfarin Dose Prediction in Chinese Patients

Construction and Validation of A Pharmacogenetic Refinement Algorithm for the Estimation of the Warfarin Dose in Chinese Patients

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients

Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients

Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm.

Impact of VKORC1 Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement--a Systematic Review and Meta Analysis.

Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation

To Establish a Method for Detecting Genetic Polymorphism of CYP2C9 1075A>C and VKORC1-1639 G>A and Evaluate the Correlation of SNP with Warfarin Dose

Polymorphisms in the Genes for Coagulation Factor II, V, VII in Patients Undergoing Coronary Angiography

Genetic factors contribute to patient-specific warfarin dose for Han Chinese.

Effect of Multiple Single-Nucleotide Variants in VKORC1 Gene on the Maintenance Doses of Warfarin

Influence of CYP4F2 Genotype on Warfarin Dose Requirement–a Systematic Review and Meta-Analysis